RXi Pharmaceuticals Corporation (NasdaqCM:RXII) acquired MirImmune Inc. on January 6, 2017. As a part of transaction, MirImmune shareholders will initially receive a total of approximately 2.75 million shares of the RXi's common stock and an additional 1.1 million shares of Series C Preferred Stock, which is convertible 1:1 into common stock, subject to receipt of stockholder approval. The purchase price is subject to adjustments. MirImmune Inc.'s shareholders will also be entitled to receive an additional consideration contingent upon the achievement of certain milestones. As part a contingent consideration payment, RXi Pharmaceuticals Corporation will either issue a number of shares of Common Stock equal to the sum of 2.52 million shares of common stock or pay the cash equivalent value of the milestone shares in cash to the sellers, subject to certain adjustments. Alexey Eliseev has been appointed as Chief Business Officer for RXi. Peter B. Finn of Rubin and Rudman LLP acted as legal advisor for sellers. Ryan A. Murr of Gibson, Dunn & Crutcher LLP acted as legal advisor for RXi Pharmaceuticals Corporation. RXi Pharmaceuticals Corporation (NasdaqCM:RXII) completed the acquisition of MirImmune Inc. on January 9, 2017.